Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospira Targets First U.S. Biosimilar Filing In 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

The generic specialty injectables firm expects to file a biosimilar version of Amgen’s Epogen in the U.S. in late 2014, potentially positioning it for its first U.S. biosimilar launch in late 2015.

You may also be interested in...



FDA Wants Biosimilar Naming Guidance Released Before Approving An Application

The agency’s policy, planning and legislation chief says FDA hopes a draft guidance is released before the first application is reviewed.

As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada

The first biosimilar MAb approval in Canada could mean Korea’s Celltrion and its partner Hospira are getting closer to filing in the U.S.

As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada

The first biosimilar MAb approval in Canada could mean Korea’s Celltrion and its partner Hospira are getting closer to filing in the U.S.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel